Male breast cancer: a disease distinct from female breast cancer
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
PurposeMale breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide. Because male BC is rare, not much is known about the disease, and treatment recommendations are typically extrapolated from data available from clinical trials enrolling female BC patients.MethodsWe review the epidemiology, risk factors, prognosis, and the varied molecular and clinicopathologic features that characterize male BC. In addition, we summarize the available data for the use of systemic therapy in the treatment of male BC and explore the ongoing development of targeted therapeutic agents for the treatment of this subgroup of BCs.ResultsThere are important biological differences between male and female BC. Male BC is almost exclusively hormone receptor positive (+), including the androgen receptor (AR), and is associated with an increased prevalence of BRCA2 germline mutations, especially in men with increased risk for developing high-risk BC. Additional research is warranted to better characterize male BC. To accomplish this, a multi-national consortium approach, such as the International Male Breast Cancer Program, is needed in response to the scarcity of patients. This approach allows the pooling of information from a large number of men with BC and the creation of registries for future therapeutic-focused clinical trials.ConclusionsGiven the unique biology of BC in men, promising new therapeutic targets are currently under investigation, including the use of poly-ADP-ribose polymerase inhibitors or AR-targeted agents either as monotherapy or in combination with other agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Self-citationGenetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBreast carcinoma in men: A population‐based study
Giordano, S. H., Cohen, D. S., Buzdar, A. U., Perkins, G., & Hortobagyi, G. N. (2004) · Cancer · doi:10.1002/cncr.20312 · Cited by 789
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Self-citationFentiman, I. S., Fourquet, A., & Hortobagyi, G. N. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68226-3 · Cited by 744
Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma
Li, C. I., Anderson, B. O., Daling, J. R., & Moe, R. E. (2003) · JAMA · doi:10.1001/jama.289.11.1421 · Cited by 577
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
Anderson, W. F., Jatoi, I., Tse, J., & Rosenberg, P. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8162 · Cited by 495
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Korde, L. A., Zujewski, J. A., Kamin, L., Giordano, S., Domchek, S., Anderson, W. F., Bartlett, J. M. S., Gelmon, K., Nahleh, Z., Bergh, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5729 · Cited by 487
Self-citationRole of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3599 · Cited by 427
Self-citationEpidemiology of male breast cancer
Konduri, S., Singh, M., Bobustuc, G., Rovin, R., & Kassam, A. (2020) · The Breast · doi:10.1016/j.breast.2020.08.010 · Cited by 411
Cardoso, F., Bartlett, J. M. S., Slaets, L., van Deurzen, C. H. M., van Leeuwen-Stok, E., Porter, P., Linderholm, B., Hedenfalk, I., Schröder, C., Martens, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx651 · Cited by 405
Self-citationCollins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., & Tamimi, R. M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.54 · Cited by 387
Epidemiology of Male Breast Cancer
Weiss, J. R., Moysich, K. B., & Swede, H. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.20.14.1 · Cited by 328
Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome
Joshi, M., Lee, A. K. C., Loda, M. F., Camus, M. G., Pedersen, C. A., Heatley, G. J., & Hughes, K. S. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960201)77:3<490::aid-cncr10>3.0.co;2-# · Cited by 233
Symmers, W. S. (1968) · BMJ · doi:10.1136/bmj.2.5597.83 · Cited by 224
Prevalence of Klinefelter's syndrome in male breast cancer patients.
Hultborn, R., Hanson, C., Köpf, I., Verbiené, I., Warnhammar, E., & WEIMARCK, A. (1998) · PubMed · Cited by 218
Carcinoma of the breast in males
Donegan, W. L., Redlich, P. N., Lang, P., & Gall, M. T. (1998) · Cancer · Cited by 206
Estrogen Suppression in Males: Metabolic Effects1
Mauras, N., O’Brien, K. O., Klein, K. O., & Hayes, V. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6676 · Cited by 190
Ottini, L., Palli, D., Rizzo, S., Federico, M., Bazan, V., & Russo, A. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.04.003 · Cited by 190
Moredo Anelli, T. F., Anelli, A., Tran, K. N., Lebwohl, D. E., & Borgen, P. I. (1994) · Cancer · doi:10.1002/1097-0142(19940701)74:1<74::aid-cncr2820740113>3.0.co;2-# · Cited by 180
A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer
Karami, F., & Mehdipour, P. (2013) · BioMed Research International · doi:10.1155/2013/928562 · Cited by 173
The Genomic Landscape of Male Breast Cancers
Piscuoglio, S., Ng, C. K. Y., Murray, M. P., Guerini‐Rocco, E., Martelotto, L. G., Geyer, F. C., Bidard, F., Berman, S., Fusco, N., Sakr, R. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2840 · Cited by 172
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
Eggemann, H., Ignatov, A., Smith, B. J., Altmann, U., von Minckwitz, G., Röhl, F. W., Jahn, M., & Costa, S.-D. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2355-3 · Cited by 164
Traina, T. A., Miller, K., Yardley, D. A., O'Shaughnessy, J., Cortes, J., Awada, A., Kelly, C. M., Trudeau, M. E., Schmid, P., Gianni, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1003 · Cited by 164
Self-citationMale breast cancer in a multi-gene panel testing cohort: insights and unexpected results
Pritzlaff, M., Summerour, P., McFarland, R. E., Li, S., Reineke, P., Dolinsky, J. S., Goldgar, D. E., Shimelis, H., Couch, F. J., Chao, E., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4085-4 · Cited by 153
Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx036 · Cited by 152
Self-citationJohansson, I., Nilsson, C., Berglund, P., Lauss, M., Ringnér, M., Olsson, H. L., Luts, L., Sim, E., Thorstenson, S., Fjällskog, M.-L., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3116 · Cited by 139
Adjuvant Chemotherapy in Males with Cancer of the Breast
Bagley, C. S., Wesley, M. N., Young, R. C., & Lippman, M. E. (1987) · American Journal of Clinical Oncology · doi:10.1097/00000421-198702000-00013 · Cited by 133
Rahim, B. G., & O'Regan, R. M. (2017) · Cancers · doi:10.3390/cancers9030021 · Cited by 132
kConFab Investigators, Silvestri, V., EMBRACE, Barrowdale, D., Mulligan, A. M., Neuhausen, S. L., Fox, S. B., Karlan, B. Y., Mitchell, G., James, P. A., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0671-y · Cited by 118
Male breast cancer: genetics, epigenetics, and ethical aspects
Rizzolo, P., Silvestri, V., Tommasi, S., Pinto, R., Danza, K., Falchetti, M., Gulino, M., Frati, P., & Ottini, L. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt316 · Cited by 115
Greene, M. H. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.1.54 · Cited by 104
A polymorphism in the CYP17 gene is associated with male breast cancer
Young, I., Kurian, K. M., Annink, C. E., Kunkler, I. H., Anderson, V. A., Cohen, B. B., Hooper, M. L., Wyllie, A. H., & Steel, C. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690663 · Cited by 99
Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence
Visram, H., Kanji, F., & Dent, S. F. (2010) · Current Oncology · doi:10.3747/co.v17i5.631 · Cited by 93
Aromatase inhibition in male breast cancer patients: biological and clinical implications
Doyen, J., Italiano, A., Largillier, R., Ferrero, J.-M., Fontana, X., & Thyss, A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp450 · Cited by 87
Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
Imamura, Y., & Sadar, M. D. (2016) · International Journal of Urology · doi:10.1111/iju.13137 · Cited by 86
Clinical correlations of steroid receptors and male breast cancer.
Everson, R. B., Lippman, M. E., Thompson, E. B., McGuire, W. L., Wittliff, J. L., Sombre, E. R. D., Jensen, E. V., Singhakowinta, A., Brooks, S., & Neifeld, J. P. (1980) · PubMed · Cited by 85
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
Papa, A., Caruso, D., Strudel, M., Tomao, F., & Tomao, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1027-1 · Cited by 80
Breast cancer in men in the United States
Harlan, L. C., Zujewski, J. A., Goodman, M. T., & Stevens, J. L. (2010) · Cancer · doi:10.1002/cncr.25153 · Cited by 79
Characterisation of male breast cancer: a descriptive biomarker study from a large patient series
Humphries, M. P., Rajan, S. S., Honarpisheh, H., Cserni, G., Dent, J., Fulford, L. G., Jordan, L. B., Jones, J. L., Kanthan, R., Litwiniuk, M. M., et al. (2017) · Scientific Reports · doi:10.1038/srep45293 · Cited by 78
Reverse the Resistance to PARP Inhibitors
Kim, Y., Kim, A., Sharip, A., Sharip, A., Jiang, J., Yang, Q., & Xie, Y. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.17240 · Cited by 76
Trunet, P. F. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.2.319 · Cited by 69
Setiawan, V. W., Schumacher, F. R., Haiman, C. A., Stram, D. O., Albanes, D., Altshuler, D., Berglund, G. L., Buring, J. E., Calle, E. E., Clavel‐Chapelon, F., et al. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0589 · Cited by 62
Outcome of non-metastatic male breast cancer: 118 patients
Arslan, Ü. Y., Öksüzoğlu, B. Ç., Özdemir, N., Aksoy, S., Alkış, N., Gök, A., Ma, K., Gümüş, M., Berk, V., Uncu, D., et al. (2011) · Medical Oncology · doi:10.1007/s12032-011-9978-9 · Cited by 61
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
Norris, J. D., Miner, S. J., Baker, J. G., Stagg, D. B., Wardell, S. E., Park, S. H., Alley, H. M., Baldi, R. M., Yllanes, A. P., Andreano, K. J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87328 · Cited by 57
Self-citationFalchetti, M., Lupi, R., Rizzolo, P., Ceccarelli, K., Zanna, I., Calò, V., Tommasi, S., Masala, G., Paradiso, A., Gulino, A., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9689-2 · Cited by 53
PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
Rivero, J. D., & Kohn, E. C. (2017) · PubMed · Cited by 45
Doebar, S. C., Slaets, L., Cardoso, F., Giordano, S. H., Bartlett, J. M. S., Tryfonidis, K., Dijkstra, N., Schröder, C. P., van Asperen, C. J., Linderholm, B. K., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.229 · Cited by 39
Self-citationChristenson, J. L., Trepel, J. B., Ali, H. Y., Lee, S., Eisner, J. R., Baskin-Bey, E. S., ELIAS, A. D., & Richer, J. K. (2018) · Hormones and Cancer · doi:10.1007/s12672-017-0314-5 · Cited by 34
Self-citationAssociation Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis
Liang, M., Zhang, Y., Sun, C., Rizeq, F. K., Min, M., Shi, T., & Sun, Y. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0344-x · Cited by 33
A review of estrogen receptor/androgen receptor genomics in male breast cancer
Severson, T., & Zwart, W. T. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0225 · Cited by 32
Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes
Giotta, F., Acito, L., Candeloro, G., Medico, P. D., Gadaleta‐Caldarola, G., Giordano, G., Gueli, R., Lugini, A., Magri, V., Mandarà, M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0022 · Cited by 15
Stepnik, M., Spryszyńska, S., Gorzkiewicz, A., & Ferlińska, M. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/60848 · Cited by 9
Cited by
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Self-citationBreast Cancer Statistics: Recent Trends
Ahmad, A. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_1 · Cited by 308
Management of Male Breast Cancer: ASCO Guideline
Hassett, M. J., Somerfield, M. R., Baker, E. R., Cardoso, F., Kansal, K. J., Kwait, D. C., Plichta, J. K., Ricker, C., Roshal, A., Ruddy, K. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03120 · Cited by 263
Self-citation
Metadata
- Authors
- Gucalp, A., Traina, T. A., Eisner, J. R., Parker, J. S., Selitsky, S. R., Park, B. H., Elias, A. D., Baskin-Bey, E. S., & Cardoso, F.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2018-09-28
- Volume
- 173
- Issue
- 1
- Pages
- 37-48
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2893465708
- Cited by
- 392
- References
- 56
- FWCI
- 19.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.